相关实验视频

Updated: May 20, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

在晚期乳腺癌中Palbociclib和Ribociclib的现实有效性

Tugay Avci¹, Mustafa Sahbazlar¹, Ferhat Ekinci¹

¹Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.

Current oncology (Toronto, Ont.)

|March 26, 2025

概括

循环素依赖性激酶4/6 (CDK 4/6) 抑制剂如利博西基利布和帕尔博西基利布在转移性激素受体阳性 (HR +) 和人体表皮生长因子受体-2 (HER2) 阴性乳腺癌 (MBC) 中表现出类似的疗效. 与palbociclib相比,ribociclib在统计学上显著地显示出更高的3年整体生存率.

科学领域:

医学瘤学医学瘤学
临床药理学临床药理学
乳腺癌研究研究乳腺癌研究

背景情况:

临床试验证实,CDK 4/6抑制剂可提高转移性HR+/HER2-乳腺癌 (MBC) 的应答率和存活率.
现实世界的数据对于支持这些CDK 4/6抑制剂疗法的疗效至关重要.
本研究评估了接受CDK 4/6抑制剂的HR+/HER2-MBC患者的治疗结果.

研究的目的:

评估HR+/HER2-MBC患者治疗CDK4/6抑制剂的治疗反应和生存期.
确定影响该患者群体治疗结果的因素.
为了比较ribociclib和palbociclib与内分泌治疗结合的疗效.

主要方法:

对120名HR+/HER2-MBC患者的回顾性分析.
患者接受了利博西基利布或博西基利布与莱特醇或富尔韦斯特兰特联合治疗.
评估无进展生存期 (PFS) 和整体生存期 (OS).

主要成果:

总体而言,PFS的中位数为24个月;里博西基利布为27个月,帕尔博西基利布为20个月 (p=0.25).
利博西克利布组合的PFS比帕尔博西克利布组合的PFS长.
三年后的OS率显著高于ribociclib (87%) 与palbociclib (55.5%) (p=0.03) 相比.

结论:

利博西克利布和帕尔博西克利布是转移HR+/HER2疾病的有效一线治疗方法.
虽然PFS与PFS相似,但 ribociclib在3年后的生存寿命中显示出统计学上显著的改善.
这些发现与随机试验一致,这些CDK 4/6抑制剂的头对头比较.

关键词:

这是一种CDK 4/6抑制剂.富尔维斯特兰特 (Fulvestrant) 是一个充满活力的项目.莱特罗佐尔 (Letrozole) 是一种转移性乳腺癌转移性乳腺癌这是palbocicliblib的意思.ribocicliblib 的意思是什么意思

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...